MAD7 Research and Development License Effective January 1, 2019Research and Development License • May 28th, 2021 • Century Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 28th, 2021 Company IndustryLicense Type Non-exclusive, non-transferable license in the Licensed Fields of Use from Inscripta, Inc. for research and development using 1) the MAD7 nuclease (as defined by SEQ ID NO:7 in U.S. Pat. No. 9,982,279); or 2) native and codon optimized nucleic acids encoding a MAD7 nuclease. 1) and 2) collectively are referred to as “MAD7”. This license in the Licensed Fields of Use is irrevocable, subject to licensee not using MAD7 in the Excluded Fields of Use below without reaching further agreement with Inscripta.
MAD7 Research and Development License Effective January 1, 2019Research and Development License • May 5th, 2021 • Century Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 5th, 2021 Company IndustryLicense Type Non-exclusive, non-transferable license in the Licensed Fields of Use from Inscripta, Inc. for research and development using 1) the MAD7 nuclease (as defined by SEQ ID NO:7 in U.S. Pat. No. 9,982,279); or 2) native and codon optimized nucleic acids encoding a MAD7 nuclease. 1) and 2) collectively are referred to as “MAD7”. This license in the Licensed Fields of Use is irrevocable, subject to licensee not using MAD7 in the Excluded Fields of Use below without reaching further agreement with Inscripta.